Reach Us +1-217-403-9671
Pros And Cons Of Ocular Bio-availability Of Drugs | 8403
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Pros and cons of ocular bio-availability of drugs

International Conference & Exhibition Bioequivalence and Bioavailability

Dr. T.Velpandian

ScientificTracks Abstracts: J Bioequiv Availab

DOI: 10.4172/0975-0851.1000001

R eaching therapeutic concentrations of antimicrobial agents through oral and topical administration for prophylactic and therapeutic use remains a challenge. Less of 5% of topically applied drugs reach anterior segment. Not more than 50% of drug levels found in the humors of the eye as compared to plasma levels after systemic administration. Maintaining a steady state antimicrobial concentration above MIC90 for most of the ocular pathogens remains elusive. Conventionally, drugs discovered for systemic diseases are developed or extrapolated for ocular use. Rather than optimizing ocular specific drugs, much of emphasis are laid on expensive and cumbersome drug delivery strategies. Ocular penetration of drugs into the humors is restricted after topical and systemic administration by well recognized ocular barriers. In our laboratory, systematic evaluation of ocular penetration studies using techniques like cassette dosing revealed the existence of Quantitative Structure Property Relationship (QSPR) among the congeneric compounds. Modulation of the influx and efflux pump mechanisms in the ocular barriers could be an alternative strategy to increase the intraocular concentration of transporter susceptible compounds. Therefore, rational drug designing strategy for ophthalmic antimicrobial agents should be envisaged. While approving drugs for ocular infections, the criteria of ocular bioavailability must be emphasized. Unlike systemic pharmacokinetic studies, ocular kinetics is different but it can be safely be performed during ophthalmic surgical procedures. A deep understanding about the disease process, presence and positioning of drug transporters and application of molecular dynamic and pharmacological interventions are the possible approaches to improve the ocular bioavailability of drugs.
Relevant Topics